

REMARKS

Claims 1, 2 and 4 currently appear in this application. The Office Action of June 27, 2006, has been carefully studied. These claims define novel and unobvious subject matter under Sections 102 and 103 of 35 U.S.C., and therefore should be allowed. Applicant respectfully requests favorable reconsideration, entry of the present amendment, and formal allowance of the claims.

Claim Objections

Claims 1-4 are objected to because calcineurin is written "calcineulin."

Claims 1 and 2 have been amended to correct this self-evident typographical error.

Rejections under 35 U.S.C. 112

Claims 1-4 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.

Claims 1, 2 and 4 are rejected under 35 U.S.C. 112, first paragraph, because the specification is said not to be enabling for SEQ ID Nos: other than 1, 2, 5 or 6.

These rejections are respectfully traversed. The claims now recite SEQ ID Nos: 1, 2, 5 and 6.

Claim 3 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement

Appln No. 10/518,710
Amd. dated September 14, 2006
Reply to Office Action June 27, 2006

requirement.

As the present amendment cancels claim 3, this rejection is now moot.

In view of the above, it is respectfully submitted that the claims are now in condition for allowance, and favorable action thereon is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By:



Anne M. Kornbau
Registration No. 25,884

AMK:srd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\A\asah\Matsui9\Pto\2006-09-14 AMD.doc